Pyotr Telyuk

Oct 22, 2024 | mdpi.com | Uma Heidi Schuth |Kieran Gill |Pyotr Telyuk |Bilal-Reshad Bawamia

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Oct 9, 2024 | preprints.org | Uma Heidi Schuth |Kieran Gill |Bilal Bawamia |Pyotr Telyuk

Preprint Review Version 1 This version is not peer-reviewed Version 1 : Received: 8 October 2024 / Approved: 8 October 2024 / Online: 9 October 2024 (09:25:50 CEST) Schuth, U. H.; Gill, K.; Bawamia, B.; Telyuk, P.; Austin, D.; Zaman, A. G. Role of Lipoprotein(a) Reduction in Cardiovascular Disease. Preprints 2024, 2024100673. https://doi.org/10.20944/preprints202410.0673.v1 Schuth, U. H.; Gill, K.; Bawamia, B.; Telyuk, P.; Austin, D.; Zaman, A. G.

Aug 1, 2024 | bjcardio.co.uk | David Austin |Paul Williams |Ahai Luvai |Pyotr Telyuk

Large-scale observational data have demonstrated a robust, independent association of elevated lipoprotein(a) (Lp[a]) levels with atherosclerotic cardiovascular disease (CVD), stroke, and peripheral artery disease. Elevated Lp(a) concentrations in patients with ischaemic heart disease have been linked to higher rates of peri-procedural myocardial infarction (MI) during percutaneous coronary intervention (PCI).